肺结节病中的中心性支气管变形:胸部影像上提示上叶纤维化表型的一个征象
回顾性队列纳入72例肺结节病(排除仅有双侧肺门淋巴结肿大者),比较有/无中心性支气管变形(CBD)组的影像结构重塑。CBD与上叶萎缩(81.4% vs 8.9%)、囊性/低衰减区(44.4% vs 6.7%)、胸膜/胸膜下增厚(59.2% vs 3.7%)高度相关,且CBD组%FVC和%DLCO更低。作者认为CBD可能是识别上叶纤维化改变的重要临床表型。
要点
- CBD与上叶萎缩高度相关(81.4% vs 8.9%,多变量OR 39.9)。
- CBD与胸膜/胸膜下增厚相关(59.2% vs 3.7%,多变量OR 68.7)。
- CBD组%FVC和%DLCO更低,提示呼吸功能障碍。
核心结论
- CBD与肺结构重塑(上叶萎缩、囊性/低衰减区、牵拉性支气管扩张、胸膜/胸膜下增厚)及呼吸功能障碍显著相关,可能是识别上叶纤维化改变的重要临床表型。
研究设计与样本
- 回顾性队列研究,纳入72例肺结节病患者,排除仅有双侧肺门淋巴结肿大者,分为有CBD组和无CBD组,在胸部影像上评估结构重塑及呼吸功能。
关键影像表现/征象
- CBD与上叶萎缩高度相关:有CBD组81.4% vs 无CBD组8.9%。
- CBD与囊性/低衰减区样肺气肿相关:有CBD组44.4% vs 无CBD组6.7%。
- CBD与胸膜/胸膜下增厚相关:有CBD组59.2% vs 无CBD组3.7%。
- 牵拉性支气管扩张常与CBD相关:有CBD组22.25% vs 无CBD组4.4%。
诊断标准与关键数值
- 上叶萎缩:单变量OR 45.1,多变量OR 39.9。
- 囊性/低衰减区样肺气肿:单变量OR 11.2,多变量OR 14.2。
- 胸膜/胸膜下增厚:单变量OR 64.0,多变量OR 68.7。
- 牵拉性支气管扩张:单变量OR 6.14。
临床应用与阅片要点
- 作者认为CBD可能是识别上叶纤维化改变的重要临床表型。
- 有CBD的患者%FVC和%DLCO更低,提示呼吸功能障碍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Bronchial and lung parenchymal structural remodeling may occur due to disease progression in patients with pulmonary sarcoidosis; however, its mechanisms remain unclear. Central bronchial deformity (CBD) associated with shrinkage in the upper lobe (SUL) is often observed in such patients. This study aimed to examine the association between CBD and structural remodeling to identify features indicating disease severity on chest images.
MATERIALS AND METHODS: This retrospective cohort study included 72 patients with pulmonary sarcoidosis, excluding patients with only bilateral hilar lymphadenopathy. The participants were divided into with and without CBD groups to examine the association between CBD and other structural remodeling, including SUL, cyst and/or low attenuation area-like emphysema (Cyst/LAA), pleural/sub-pleural thickening (PT), and traction bronchiectasis (TrBE), in the upper lobe on chest images. The association of CBD phenotype with respiratory dysfunction was also examined.
RESULTS: CBD was highly associated with SUL (81.4% vs. 8.9%), Cyst/LAA (44.4% vs. 6.7%), and PT (59.2% vs. 3.7%). The respective odds ratios in the univariable and multivariable analyses were as follows: SUL, 45.1 and 39.9; Cyst/LAA, 11.2 and 14.2; and PT, 64.0 and 68.7. TrBE was frequently associated with CBD (22.25% vs. 4.4%); the odds ratio was 6.14 in the univariable analysis. Furthermore, participants with CBD exhibited lower %FVC and %DLCO.
CONCLUSION: CBD is significantly associated with lung remodeling (SUL, Cyst/LAA, TrBE, and PT) and respiratory dysfunction. CBD may be a crucial clinical phenotype to identify upper lobe fibrotic changes.
引用
- Kawanobe T, Yamaguchi T, Johkoh T, et al. Central Bronchial Deformity in Pulmonary Sarcoidosis: A Finding Suggestive of an Upper Lobe Fibrotic Phenotype on Chest Images. Acad Radiol. 2023. PMID: 37743162. doi:10.1016/j.acra.2023.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。